Institution
University of Milano-Bicocca
Education•Milan, Italy•
About: University of Milano-Bicocca is a education organization based out in Milan, Italy. It is known for research contribution in the topics: Population & Blood pressure. The organization has 8972 authors who have published 22322 publications receiving 620484 citations. The organization is also known as: Università degli Studi di Milano-Bicocca & Universita degli Studi di Milano-Bicocca.
Papers published on a yearly basis
Papers
More filters
••
01 Mar 2004TL;DR: In this paper, it is shown how to improve the chiral behaviour and the approach to the continuum limit of correlation functions in lattice QCD with standard and twisted Wilson fermions by taking arithmetic averages of correlators computed in theories regularized with Wilson terms of opposite sign.
Abstract: It is possible to improve the chiral behaviour and the approach to the continuum limit of correlation functions in lattice QCD with standard and twisted Wilson fermions by taking arithmetic averages of correlators computed in theories regularized with Wilson terms of opposite sign. To avoid the problem of the spurious zero-modes of the Wilson-Dirac operator, twisted-mass lattice QCD should be used for the actual computation of the correlators taking part in the averages. A particularly useful choice for the twisting angle is ±π 2 where many physical quantities (e.g. masses and zero-momentum matrix elements) are automatically improved with no need of averaging.
260 citations
••
TL;DR: A potential for therapeutic use of cannabidiol in chronic painful states is indicated after the compound's efficacy on neuropathic pain was not accompanied by any reduction in nuclear factor-kappaB activation and tumor necrosis factor alpha content.
259 citations
••
TL;DR: Empalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis and was not associated with any organ toxicity.
Abstract: Background Primary hemophagocytic lymphohistiocytosis is a rare syndrome characterized by immune dysregulation and hyperinflammation. It typically manifests in infancy and is associated wi...
259 citations
••
TL;DR: This analysis assessed the associations between mean blood pressure achieved on treatment; prerandomisation baseline blood pressure; or time-updated blood pressure on the composite outcome of cardiovascular death, myocardial infarction, stroke, and hospital admission for heart failure; the components of the Composite outcome; and all-cause death.
259 citations
••
McMaster University1, University of Washington2, United Arab Emirates University3, Copenhagen University Hospital4, St Thomas' Hospital5, University of Michigan6, King Saud bin Abdulaziz University for Health Sciences7, Albert Einstein College of Medicine8, University of Toronto9, Rhode Island Hospital10, Brown University11, Utrecht University12, NewYork–Presbyterian Hospital13, Peking Union Medical College Hospital14, Federal University of São Paulo15, Humanitas University16, University of Ulsan17, National Institutes of Health18, Jagiellonian University Medical College19, Population Health Research Institute20, University of Manitoba21, University at Buffalo22, Homi Bhabha National Institute23, Baylor College of Medicine24, Vanderbilt University25, University of Milano-Bicocca26, King Saud Medical City27, Royal North Shore Hospital28, The George Institute for Global Health29, University of Virginia30, University of Dammam31, Emory University32, University of Pennsylvania33, Agostino Gemelli University Polyclinic34, St George’s University Hospitals NHS Foundation Trust35
TL;DR: The Surviving Sepsis Campaign Coronavirus Diease 2019 (SCCD) 2019 panel as mentioned in this paper provided guidance on the management of patients with severe or critical coronavirus disease 2019 in the ICU.
Abstract: Background The coronavirus disease 2019 pandemic continues to affect millions worldwide. Given the rapidly growing evidence base, we implemented a living guideline model to provide guidance on the management of patients with severe or critical coronavirus disease 2019 in the ICU. Methods The Surviving Sepsis Campaign Coronavirus Disease 2019 panel has expanded to include 43 experts from 14 countries; all panel members completed an electronic conflict-of-interest disclosure form. In this update, the panel addressed nine questions relevant to managing severe or critical coronavirus disease 2019 in the ICU. We used the World Health Organization's definition of severe and critical coronavirus disease 2019. The systematic reviews team searched the literature for relevant evidence, aiming to identify systematic reviews and clinical trials. When appropriate, we performed a random-effects meta-analysis to summarize treatment effects. We assessed the quality of the evidence using the Grading of Recommendations, Assessment, Development, and Evaluation approach, then used the evidence-to-decision framework to generate recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Results The Surviving Sepsis Campaign Coronavirus Diease 2019 panel issued nine statements (three new and six updated) related to ICU patients with severe or critical coronavirus disease 2019. For severe or critical coronavirus disease 2019, the panel strongly recommends using systemic corticosteroids and venous thromboprophylaxis but strongly recommends against using hydroxychloroquine. In addition, the panel suggests using dexamethasone (compared with other corticosteroids) and suggests against using convalescent plasma and therapeutic anticoagulation outside clinical trials. The Surviving Sepsis Campaign Coronavirus Diease 2019 panel suggests using remdesivir in nonventilated patients with severe coronavirus disease 2019 and suggests against starting remdesivir in patients with critical coronavirus disease 2019 outside clinical trials. Because of insufficient evidence, the panel did not issue a recommendation on the use of awake prone positioning. Conclusion The Surviving Sepsis Campaign Coronavirus Diease 2019 panel issued several recommendations to guide healthcare professionals caring for adults with critical or severe coronavirus disease 2019 in the ICU. Based on a living guideline model the recommendations will be updated as new evidence becomes available.
257 citations
Authors
Showing all 9226 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carlo Rovelli | 146 | 1502 | 103550 |
Giuseppe Mancia | 145 | 1369 | 139692 |
Marco Bersanelli | 142 | 526 | 105135 |
Teruki Kamon | 142 | 2034 | 115633 |
Marco Colonna | 139 | 512 | 71166 |
M. I. Martínez | 134 | 1251 | 79885 |
A. Mennella | 132 | 463 | 93236 |
Roberto Salerno | 132 | 1197 | 83409 |
Federico Ferri | 132 | 1376 | 89337 |
Marco Paganoni | 132 | 1438 | 88482 |
Arabella Martelli | 131 | 1318 | 84029 |
Sandra Malvezzi | 129 | 1326 | 84401 |
Andrea Massironi | 129 | 1115 | 78457 |
Marco Pieri | 129 | 1285 | 82914 |
Cristina Riccardi | 129 | 1627 | 91452 |